Discover open access scientific publications

Search, annotate, share and cite publications

Publications by John W Hanrahan

Low Free Drug Concentration Prevents Inhibition of F508del CFTR Functional Expression by the Potentiator VX-770 (Ivacaftor)

British Journal of Pharmacology

Pharmacology

2016

English

Related publications

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-Dependent but ATP-independent Manner

Journal of Biological Chemistry

English

VX-770-mediated Potentiation of Numerous Human CFTR Disease Mutants Is Influenced by Phosphorylation Level

Scientific Reports

Multidisciplinary

2019

English

Functional Rescue of F508del-CFTR Using Small Molecule Correctors

Frontiers in Pharmacology

Pharmacology

2012

English

Combination Potentiator (‘Co-Potentiator’) Therapy for CF Caused by CFTR Mutants, Including N1303K, That Are Poorly Responsive to Single Potentiators

Journal of Cystic Fibrosis

English

A Kinase-Directed Approach to Rescue Functionality of F508del CFTR

Postdoc Journal

2016

English

Prs16 - Modeled Survival Gains of Patients With Cystic Fibrosis (Cf) Aged ≥12 Years Heterozygous for F508del-CFTR and a Residual Function Mutation (F508del/Rf) Treated With the Cf Transmembrane Conductance Regulator Modulator (Cftrm) Tezacaftor/Ivacaftor (Tez/Iva)

English

Biophysical Characterisation of Calumenin as a Charged F508del-CFTR Folding Modulator

PLoS ONE

Multidisciplinary

2014

English

Cysteamine Re-Establishes the Clearance of Pseudomonas Aeruginosa by Macrophages Bearing the Cystic Fibrosis-Relevant F508del-CFTR Mutation

Cell Death and Disease

Molecular Neuroscience

English

Functional Inhibition of Chemokine Receptor CCR2 by Dicer-Substrate-siRNA Prevents Pain Development

Molecular Neuroscience

2016

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by John W Hanrahan

Low Free Drug Concentration Prevents Inhibition of F508del CFTR Functional Expression by the Potentiator VX-770 (Ivacaftor)

Related publications

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-Dependent but ATP-independent Manner

VX-770-mediated Potentiation of Numerous Human CFTR Disease Mutants Is Influenced by Phosphorylation Level

Functional Rescue of F508del-CFTR Using Small Molecule Correctors

Combination Potentiator (‘Co-Potentiator’) Therapy for CF Caused by CFTR Mutants, Including N1303K, That Are Poorly Responsive to Single Potentiators

A Kinase-Directed Approach to Rescue Functionality of F508del CFTR

Prs16 - Modeled Survival Gains of Patients With Cystic Fibrosis (Cf) Aged ≥12 Years Heterozygous for F508del-CFTR and a Residual Function Mutation (F508del/Rf) Treated With the Cf Transmembrane Conductance Regulator Modulator (Cftrm) Tezacaftor/Ivacaftor (Tez/Iva)

Biophysical Characterisation of Calumenin as a Charged F508del-CFTR Folding Modulator

Cysteamine Re-Establishes the Clearance of Pseudomonas Aeruginosa by Macrophages Bearing the Cystic Fibrosis-Relevant F508del-CFTR Mutation

Functional Inhibition of Chemokine Receptor CCR2 by Dicer-Substrate-siRNA Prevents Pain Development